Senores Pharmaceuticals Limited (SPL) saw its stock jump 5% to reach day high of Rs 565.00 after its US subsidiary, Senores Pharmaceuticals, Inc. (SPI), signed an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Roflumilast 250 mcg and 500 mcg tablets from Breckenridge Pharmaceutical, Inc., a subsidiary of Towa International.
Roflumilast, a critical treatment for severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis, represents a significant market opportunity. According to IQVIA (MAT June 2024), the US market for Roflumilast is valued at approximately USD 32 million, while Symphony (MAT September 2024) estimates it at USD 46 million.
This strategic acquisition, funded by SPL’s IPO proceeds, strengthens its specialty distribution portfolio and enhances its footprint in chronic bronchitis therapy.
Senores Pharmaceuticals’ shares opened at ₹540.00, reaching a high of ₹565.00 and a low of ₹540.00. The stock remains below its 52-week high of ₹644.80 but above its 52-week low of ₹435.25.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
